Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Showing 1-25 of 190 citing articles:

Kinase inhibitors: the road ahead
Fleur M. Ferguson, Nathanael S. Gray
Nature Reviews Drug Discovery (2018) Vol. 17, Iss. 5, pp. 353-377
Closed Access | Times Cited: 891
PROteolysis TArgeting Chimeras (PROTACs) — Past, present and future
Mariell Pettersson, Craig M. Crews
Drug Discovery Today Technologies (2019) Vol. 31, pp. 15-27
Open Access | Times Cited: 594
A Potent and Selective Small-Molecule Degrader of STAT3 Achieves Complete Tumor Regression In Vivo
Longchuan Bai, Haibin Zhou, Renqi Xu, et al.
Cancer Cell (2019) Vol. 36, Iss. 5, pp. 498-511.e17
Open Access | Times Cited: 483
BAF complex vulnerabilities in cancer demonstrated via structure-based PROTAC design
William Farnaby, Manfred Koegl, Michael J. Roy, et al.
Nature Chemical Biology (2019) Vol. 15, Iss. 7, pp. 672-680
Open Access | Times Cited: 467
Differential PROTAC substrate specificity dictated by orientation of recruited E3 ligase
Blake E. Smith, Stephen L. Wang, Saul Jaime‐Figueroa, et al.
Nature Communications (2019) Vol. 10, Iss. 1
Open Access | Times Cited: 443
PROTACs: past, present and future
Ke Li, Craig M. Crews
Chemical Society Reviews (2022) Vol. 51, Iss. 12, pp. 5214-5236
Open Access | Times Cited: 419
Bromodomains: a new target class for drug development
Andrea G. Cochran, Andrew R. Conery, Robert J. Sims
Nature Reviews Drug Discovery (2019) Vol. 18, Iss. 8, pp. 609-628
Closed Access | Times Cited: 375
Proteolysis targeting chimeras (PROTACs) in ‘beyond rule-of-five’ chemical space: Recent progress and future challenges
Scott D. Edmondson, Bin Yang, Charlene Fallan
Bioorganic & Medicinal Chemistry Letters (2019) Vol. 29, Iss. 13, pp. 1555-1564
Closed Access | Times Cited: 316
Small-molecule PROTACs: An emerging and promising approach for the development of targeted therapy drugs
Sainan An, Liwu Fu
EBioMedicine (2018) Vol. 36, pp. 553-562
Open Access | Times Cited: 301
SPR-Measured Dissociation Kinetics of PROTAC Ternary Complexes Influence Target Degradation Rate
Michael J. Roy, Sandra Winkler, Scott J. Hughes, et al.
ACS Chemical Biology (2019) Vol. 14, Iss. 3, pp. 361-368
Open Access | Times Cited: 295
Iterative Design and Optimization of Initially Inactive Proteolysis Targeting Chimeras (PROTACs) Identify VZ185 as a Potent, Fast, and Selective von Hippel–Lindau (VHL) Based Dual Degrader Probe of BRD9 and BRD7
Vittoria Zoppi, Scott J. Hughes, Chiara Maniaci, et al.
Journal of Medicinal Chemistry (2018) Vol. 62, Iss. 2, pp. 699-726
Open Access | Times Cited: 292
Mapping the Degradable Kinome Provides a Resource for Expedited Degrader Development
Katherine A. Donovan, Fleur M. Ferguson, Jonathan W. Bushman, et al.
Cell (2020) Vol. 183, Iss. 6, pp. 1714-1731.e10
Open Access | Times Cited: 282
MDM2-Recruiting PROTAC Offers Superior, Synergistic Antiproliferative Activity via Simultaneous Degradation of BRD4 and Stabilization of p53
John Hines, Schan Lartigue, Hanqing Dong, et al.
Cancer Research (2018) Vol. 79, Iss. 1, pp. 251-262
Open Access | Times Cited: 277
Current strategies for the design of PROTAC linkers: a critical review
Robert I. Troup, Charlene Fallan, Matthias G. J. Baud
Exploration of Targeted Anti-tumor Therapy (2020) Vol. 1, Iss. 5
Open Access | Times Cited: 249
Molecular recognition of ternary complexes: a new dimension in the structure-guided design of chemical degraders
Scott J. Hughes, Alessio Ciulli
Essays in Biochemistry (2017) Vol. 61, Iss. 5, pp. 505-516
Open Access | Times Cited: 212
Proteolysis targeting chimera (PROTAC) in drug discovery paradigm: Recent progress and future challenges
Shenxin Zeng, Wenhai Huang, Xiaoliang Zheng, et al.
European Journal of Medicinal Chemistry (2020) Vol. 210, pp. 112981-112981
Closed Access | Times Cited: 164
Recent Developments in PROTAC‐Mediated Protein Degradation: From Bench to Clinic
Zhenyi Hu, Craig M. Crews
ChemBioChem (2021) Vol. 23, Iss. 2
Open Access | Times Cited: 158
In Silico Modeling of PROTAC-Mediated Ternary Complexes: Validation and Application
Michael L. Drummond, Christopher I. Williams
Journal of Chemical Information and Modeling (2019) Vol. 59, Iss. 4, pp. 1634-1644
Open Access | Times Cited: 153
Degradation of Polycomb Repressive Complex 2 with an EED-Targeted Bivalent Chemical Degrader
Frances Potjewyd, Anne‐Marie W. Turner, Joshua Beri, et al.
Cell chemical biology (2019) Vol. 27, Iss. 1, pp. 47-56.e15
Open Access | Times Cited: 152
Unraveling the Role of Linker Design in Proteolysis Targeting Chimeras
Troy A. Bemis, James J. La Clair, Michael D. Burkart
Journal of Medicinal Chemistry (2021) Vol. 64, Iss. 12, pp. 8042-8052
Closed Access | Times Cited: 151
Antibody Conjugation of a Chimeric BET Degrader Enables in vivo Activity
Thomas H. Pillow, Pragya Adhikari, Robert A. Blake, et al.
ChemMedChem (2019) Vol. 15, Iss. 1, pp. 17-25
Closed Access | Times Cited: 150
Target and tissue selectivity of PROTAC degraders
Robert G. Guenette, Seung Wook Yang, Jaeki Min, et al.
Chemical Society Reviews (2022) Vol. 51, Iss. 14, pp. 5740-5756
Closed Access | Times Cited: 147
Solution Conformations Shed Light on PROTAC Cell Permeability
Yoseph Atilaw, Vasanthanathan Poongavanam, Caroline Svensson Nilsson, et al.
ACS Medicinal Chemistry Letters (2020) Vol. 12, Iss. 1, pp. 107-114
Open Access | Times Cited: 142
Antibody-Mediated Delivery of Chimeric BRD4 Degraders. Part 2: Improvement of In Vitro Antiproliferation Activity and In Vivo Antitumor Efficacy
Peter S. Dragovich, Thomas H. Pillow, Robert A. Blake, et al.
Journal of Medicinal Chemistry (2021) Vol. 64, Iss. 5, pp. 2576-2607
Closed Access | Times Cited: 136
From Conception to Development: Investigating PROTACs Features for Improved Cell Permeability and Successful Protein Degradation
Carlotta Cecchini, Sara Pannilunghi, Sébastien Tardy, et al.
Frontiers in Chemistry (2021) Vol. 9
Open Access | Times Cited: 123
Page 1 - Next Page

Scroll to top